Pharma stocks update: Drug firm Aurobindo pharmaceutical company on October 11, 2018, said it’s received final nod from the US health regulator for its Azithromycin Oral suspension used for treatment of infections.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin Oral suspension a hundred mg /5 millilitre and two hundred mg/5 millilitre, Aurobindo pharmaceutical company aforesaid in an exceedingly statement.
The product could be a generic version of Pfizer Inc’s Zithromax oral suspension, it added. Pfizer Ltd. key Products/Revenue Segments embrace prescription drugs that contributed Rs 2017.26 large integer to Sales worth (98.79 percent Total Sales), Sale of services that contributed Rs twenty four.59 large integer to Sales worth (1.20 percent Total Sales), Scrap that contributed Rs .08 large integer to Sales worth (0.00 percent Total Sales)for the year ending 31-Mar-2017.
According to IQVIA in pharma stocks, the approved product has associate degree calculable market size of USD seventy one million for the twelve months ending August 2018, Aurobindo pharmaceutical company aforesaid. The corporate currently features a total of 386 abbreviated new drug application (ANDA) approvals (357 final approvals as well as nineteen from Aurolife pharmaceutical company LLC and twenty nine tentative approvals) from the USFDA, it added.
Quoting IQVIA sales information, the corporate aforesaid, the approved product has associate degree calculable market size of USD 132 million for the twelve months ending might 2018.
Aurobindo pharmaceutical company presently features a total of 337 ANDA approvals (344 final approvals as well as seventeen from Aurolife pharmaceutical company and thirty five tentative approvals) from the US.
Azithromycin oral suspension, a generic version of Pfizer Inc’s Zithromax oral suspension. The merchandise is going to be launched in Nov 2018, company said in release, according to the report of Moneycontrol.
Pharma stocks of Aurobindo pharmaceutical company were commercialism at Rs 773.75 per scrip on the BSE, down by 0.58 percent from its previous shut, according to the report of Economic Times.
The post Pharma Stocks News: Aurobindo Pharma Drops 3 Percent & Receives Final NOD From US Health Regulator For Azithromycin Oral Suspension appeared first on OWLT Market.
from OWLT Market https://ift.tt/2CHalgj
via IFTTThttps://ift.tt/2OlCCL9
No comments:
Post a Comment